Patrick Vizeli
Postdoctoral Researcher in Clinical Pharmacology
Data updated
Research Footprint
Patrick Vizeli appears in 26 tracked papers (2017–2026), most studied alongside MDMA, LSD and Placebo, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. (248 citations).
Frequent co-authors: Matthias Liechti, Friederike Holze and Lukas Ley.
Publication Landscape
How the 26 papers Blossom tracks for Patrick Vizeli line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Patrick Vizeli's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 26 of 26 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Patrick Vizeli publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Patrick Vizeli publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Patrick Vizeli is a researcher at the University of California San Diego and the University of Basel. His work focuses on the human pharmacology of classic psychedelics, specifically LSD. He investigates how personality traits, mood, and genetic variations impact the subjective and physiological effects of these substances, aiming to refine their therapeutic application for psychiatric and neurological disorders.
Key Impact
Investigates the pharmacogenetics and non-pharmacological factors influencing LSD response.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Patrick Vizeli's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Patrick Vizeli is associated with.
University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →University of California San Diego
academicThe Psychedelics and Health Research Initiative (PHRI) focuses heavily on conducting pilot studies and clinical trials while collecting diverse biometric data—including fMRI, EEG, and cognitive metrics—from study participants. This data-driven approach aims to unravel the biological and neurological underpinnings of how psychedelics facilitate healing.
View stakeholder →